Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.02. | Relmada acquires Tourette's therapy rights from Asarina | 5 | Pharmaceutical Technology | ||
06.02. | Relmada Therapeutics acquires potential therapy for Tourette Syndrome from Asarina Pharma | 2 | Seeking Alpha | ||
04.10.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 04.10.2024 | 791 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 04.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 04.10.2024ISIN NameCA2265331074 CREW... ► Artikel lesen | |
ASARINA PHARMA Aktie jetzt für 0€ handeln | |||||
02.10.24 | XFRA APS: AUSSETZUNG/SUSPENSION | 330 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILASARINA PHARMA AB... ► Artikel lesen | |
16.09.24 | Nasdaq Stockholm AB: Delisting of Asarina Pharma AB (publ) from Nasdaq First North Growth Market | 344 | GlobeNewswire | Asarina Pharma AB (publ) has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Asarina... ► Artikel lesen | |
13.09.24 | Nasdaq Stockholm AB: The observation status for Asarina Pharma AB (publ) is updated | 481 | GlobeNewswire | On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press
release with information that the Company intends to propose that an
extraordinary general meeting resolves that the Company... ► Artikel lesen | |
13.09.24 | Asarina Pharma AB: Asarina Pharma applies for the delisting of the company's shares | 233 | GlobeNewswire (Europe) | Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary liquidation.... ► Artikel lesen | |
19.07.24 | Nasdaq Stockholm AB: Asarina Pharma AB (publ) receives observation status | 373 | GlobeNewswire | On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press
release with information that the Company intends to propose that an
extraordinary general meeting resolves that the Company... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |